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Background: Mitochondrial dysfunction is a hallmark of neurodegenerative diseases including Alzheimer’s disease
(AD), with morphological and functional abnormalities limiting the electron transport chain and ATP production. A
contributing factor of mitochondrial abnormalities is loss of nicotinamide adenine dinucleotide (NAD), an important
cofactor in multiple metabolic reactions. Depletion of mitochondrial and consequently cellular NAD(H) levels by
activated NAD glycohydrolases then culminates in bioenergetic failure and cell death. De Novo NAD+ synthesis
from tryptophan requires a multi-step enzymatic reaction. Thus, an alternative strategy to maintain cellular NAD+
levels is to administer NAD+ precursors facilitating generation via a salvage pathway. We administered nicotinamide
mononucleotide (NMN), an NAD+ precursor to APP(swe)/PS1(ΔE9) double transgenic (AD-Tg) mice to assess amelioration
of mitochondrial respiratory deficits. In addition to mitochondrial respiratory function, we examined levels of full-length
mutant APP, NAD+-dependent substrates (SIRT1 and CD38) in homogenates and fission/fusion proteins (DRP1, OPA1
and MFN2) in mitochondria isolated from brain. To examine changes in mitochondrial morphology, bigenic mice
possessing a fluorescent protein targeted to neuronal mitochondria (CaMK2a-mito/eYFP), were administered NMN.
Methods: Mitochondrial oxygen consumption rates were examined in N2A neuroblastoma cells and non-synaptic
brain mitochondria isolated from mice (3 months). Western blotting was utilized to assess APP, SIRT1, CD38, DRP1,
OPA1 and MFN2 in brain of transgenic and non-transgenic mice (3–12 months). Mitochondrial morphology was
assessed with confocal microscopy. One-way or two-way analysis of variance (ANOVA) and post-hoc Holm-Sidak
method were used for statistical analyses of data. Student t-test was used for direct comparison of two groups.
Results: We now demonstrate that mitochondrial respiratory function was restored in NMN-treated AD-Tg mice.
Levels of SIRT1 and CD38 change with age and NMN treatment. Furthermore, we found a shift in dynamics from
fission to fusion proteins in the NMN-treated mice.
Conclusions: This is the first study to directly examine amelioration of NAD+ catabolism and changes in mitochondrial
morphological dynamics in brain utilizing the immediate precursor NMN as a potential therapeutic compound. This
might lead to well-defined physiologic abnormalities that can serve an important role in the validation of promising
agents such as NMN that target NAD+ catabolism preserving mitochondrial function.
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Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly, with aging being the most im-
portant risk factor [1]. Mitochondrial dysfunction is a
hallmark of neurodegenerative diseases with morpho-
logical and functional abnormalities limiting the electron
transport chain and adenosine triphosphate (ATP) pro-
duction seen in AD [2].
Nicotinamide adenine dinucleotide (NAD) is a cofac-
tor that is essential for many biological reactions in
either its oxidized (NAD+) or reduced (NADH) forms
[3]. NAD+ and NADH mediate transfer of hydrogens in
oxidative and reductive metabolic reactions [4]. NAD+ is
essential to many mitochondrial enzymatic reactions and
appropriate cellular bioenergetic metabolism [5,6]. NAD
+ levels naturally decline with aging [4]. In normal con-
ditions, the loss of NAD+ inhibits cellular respiration,
resulting in loss of mitochondrial ATP production and
potentially cellular death [5]. NAD+ is used as a substrate
by several NAD+ dependent enzymes including poly(ADP-
ribose) polymerase 1 (PARP1), Sirtuin 1 (SIRT1), and ADP-
ribosyl cyclase (CD38) [4,5,7,8].
Preventing NAD+ depletion and cellular energy deficits
could be a therapeutic target for neurodegenerative dis-
eases and act as a neuroprotective mechanism [7]. Four
pathways can synthesize NAD+ in mammals. NAD+ can
be synthesized from the salvage pathway (primary route)
utilizing nicotinamide, nicotinic acid, nicotinamide riboside,
or the de novo pathway using tryptophan [9]. Nicotinamide
phosphoribosyltransferase (Nampt) helps transfer a phos-
phoribosyl residue to nicotinamide forming nicotinamide
mononucleotide (NMN) [9]. NAD+ consists of NMN cova-
lently bound to adenosine monophosphate (AMP) [4]. The
enzyme NMN adenyltransferase (NMNAT) converts NMN
to NAD+ in one step [4,9,10] making NMN a key precursor
with possible therapeutic implications for increased NAD+
levels [11,12]. Further, NMN is more soluble than NAD+ in
phosphate buffered saline (PBS) and is taken up more effi-
ciently through the plasma membrane [9,13].
We have recently demonstrated in the well-studied
AD chimeric APP(swe)/PS1(ΔE9) mouse model, deficits in
mitochondrial oxygen consumption rates (OCR) in both
brain and muscle [14]. These deficits in OCR may have
resulted from lack of sufficient NAD+ due to increased
catabolism. Thus, in the present study we tested the hy-
pothesis that increasing NAD+ availability by administer-
ing the precursor NMN would reverse mitochondrial
OCR deficiencies in these AD disease-relevant animals.
Mitochondrial respiration, calcium homeostasis and
organelle transport have also been demonstrated to be
influenced by mitochondrial morphology [15,16].
Fusion of two mitochondria causes an elongated morph-
ology that can play a protective role in the nervous system,
while fission allows proper distribution of mitochondriaand is also used to remove damaged organelles [17]. Mito-
chondrial dynamics are the balance of fission and fusion,
controlling the morphology, number, and function of
mitochondria [17-19]. Abnormal changes in these
dynamics have been linked with aging and several neu-
rodegenerative diseases (e.g. AD, Huntington’s disease
(HD), Parkinson’s disease (PD), multiple sclerosis (MS),
and amyotrophic lateral sclerosis (ALS)). In these diseases
mitochondrial morphology tends to shift towards in-
creased fragmentation, indicating either an increase in fis-
sion or decreased fusion [19]. To examine changes in
mitochondrial morphology, bigenic mice possessing a
fluorescent protein targeted to neuronal mitochondria
(CaMK2a-mito/eYFP), were administered NMN.
We demonstrate restoration of OCR in the NMN-
treated AD double transgenic (AD-Tg) mice, indicating
NAD+ levels were probably limiting. To further evaluate
the basis of this effect we measured immunoreactivity of
the NAD+-consuming proteins SIRT1 and CD38 and de-
termined that they change with age as well as a function
of NMN-treatment. Furthermore, we found a shift in dy-
namics from fission to fusion proteins in the NMN
treated mice. This is the first study to directly examine
amelioration of NAD+ catabolism and changes in mito-
chondrial morphological dynamics in AD mouse brain




All chemicals were purchased from Sigma-Aldrich
(St Louis, MO) unless otherwise stated.
Animals
Alzheimer’s disease-relevant mice
Double transgenic mice expressing a chimeric mouse/
human amyloid precursor protein (APP) with the Swedish
mutation (APPswe) and a mutant human presenilin 1 (PS1)
with the delta E9 (PS1ΔE9) (strain # 005864) and wildtype
C57BL/6 mice were purchased from the Jackson
Laboratory, (Bar Harbor, ME). AD animals positive for
the transgenes were identified by polymerase chain
reaction (PCR) using genomic DNA, isolated from the
tails (Qiagen, Valencia, CA) then processed as described
previously [14].
CaMKIIα-tTA and pTRE-mito/eYFP mice
Transgenic mice expressing the tetracycline-controlled
transactivator protein (tTA) under regulatory control of
the calcium/calmodulin-dependent kinase II (CaMKII)
promoter [20] and animals expressing pTRE-mito/eYFP
[21] were purchased from the Jackson Laboratory.
Bigenic mice positive for both CaMKIIα-tTA and
pTRE-mito/eYFP (CaMK2a-mito/eYFP) were generated
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mice (2 months) were used in this study. CaMK2a-
mito/eYFP bigenic mice were identified by PCR as
described previously [21]. The University of Maryland
School of Medicine Institutional Animal Use and Care
Committee approved all procedures involving animal
care, euthanasia and tissue collection.
Nicotinamide mononucleotide (NMN) administration
APP(swe)/PS1(ΔE9) and CaMK2a-mito/eYFP male and
female mice (2 months) were administered NMN
(100 mg/kg, Sigma N3501) in sterile PBS (200 μl)
subcutaneously (in the loose skin around the neck and
shoulder area) every other day for 28 days. Non-
transgenic (NTG) and vehicle control animals were
administered 200 μl sterile PBS subcutaneously every
other day for 28 days. Subcutaneous administration
was utilized based on pilot studies. No significant
differences in weight or external characteristics (fur
condition, energy, size etc.) were observed between
NMN and vehicle treated mice (data not shown).
N2A neuroblastoma cell culture conditions
Low passage mouse N2A hippocampal neuroblastomas
(ATCC, Manassas, VA; 5,000/well) were seeded on V7
microplates (Seahorse Bioscience, North Billerica, MA)
in proliferation media ((MEM, (ATCC), 10% fetal bovine
serum, (Gibco, Grand Island, NY), 1% Pen-Strep,
(Gibco)) and maintained in a humidified incubator at
37°C and 5% CO2. After 24 h, cultures were transiently
transfected (see below). After a further 24 hours, the
proliferation media was replaced with differentiation
media (DM) consisting of MEM, 2% horse serum
(Gibco) and 1% Pen-Strep. The cultures had media
changes using DM 48 hours later and oxygen consump-
tion rates were measured 24 hours later. All wells were
critically examined under the microscope to ensure cell
viability prior to performing experiments.
Plasmid vector generation and transfection
The plasmid vector containing cDNA for a mitochondrially-
targeted enhanced yellow fluorescent protein (eYFP),
mutant APP(swe) and mutant PS1(ΔE9) described in [14]
possesses a tetracycline response element thus requiring
co-transfection with a tetracycline transactivator (TTA,
Clontech). Co-transfection gives rise to cells possessing
eYFP targeted to mitochondria and transgene-derived
APP and PS1. N2A neuroblastomas were co-transfected
with both constructs or TTA alone (control transfection)
utilizing 1 μg of DNA/construct/well using the
Magnetofection system (Oz Biosciences, San Diego, CA)
with CombiMag plus lipofectamine (Invitrogen, Carlsbad,
CA) according to the manufacturer’s protocol.Isolation of non-synaptic brain mitochondria
Twenty-four hours after the final NMN or vehicle
injections, male and female APP(swe)/PS1(ΔE9) or non-
transgenic mice (3 months) were decapitated, forebrains
rapidly removed and placed in ice-cold mannitol-sucrose
(MS) buffer pH 7.4 (225 mM mannitol, 75 mM sucrose,
5 mM Hepes, 1 mg/ml fatty acid free BSA (Roche
Diagnostics, Indianapolis, IN), 1 mM EGTA). Forebrains
were homogenized with 10 strokes using a Potter-
Elvehjem tissue grinder (Wheaton Science Products,
Millville, NJ). The brain homogenates were further proc-
essed using the Percoll isolation method described by
[22] and as used previously [14,23]. This method has
been demonstrated to show a high level of mitochon-
drial purity by electron microscopy [23]. Protein concen-
trations were determined by the method described by
[24] using BSA as standards. Aliquots of brain mito-
chondria and homogenate had protease inhibitors
(Calbiochem, San Diego, CA) added prior to storage
at −20°C for later Western blot analyses.
N2A neuroblastoma cell respirometry
Prior to measurements, cultures were gently rinsed in
pre-warmed (37°C) assay measurement buffer (MB) con-
sisting of 120 mM NaCl, 3.5 mM KCl, 1.3 mM CaCl2,
0.4 mM KH2PO4, 1 mM MgCl2, 5 mM HEPES (pH 7.4)
supplemented with 2.5 mM D-glucose. The cells were
then placed in an unbuffered, humidified incubator at
37°C for 2 hours to allow temperature and pH equilibra-
tion. Cells were visually inspected prior to and after MB
addition then loaded onto the Seahorse XF24-3 flux
analyzer (Seahorse Bioscience). After an equilibration
step, basal oxygen consumption rates (OCR, pMoles/
min) were recorded using 3-min mix, 2-min wait, and 3-
min measure (looped 3 times) cycles prior to injection of
oligomycin to inhibit the ATP synthase. Three more
measurement loops were recorded prior to injection of
carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone
(FCCP) to induce maximal oxygen consumption. Follow-
ing recording of 3 more measurement loops, pyruvate
was injected to determine if maximal oxygen consump-
tion following FCCP addition was substrate limited.
Antimycin A (inhibitor of mitochondrial respiration)
was injected after 3 measurement loops to assess non-
mitochondrial OCR. Two measurement loops were re-
corded after antimycin A injection then the experiment
was terminated. The injectates prepared in MB (75 μl
volumes) were preloaded, then sequentially injected as
indicated through ports in the XF24 calibration cartridge
to final concentrations of 1 μg/ml oligomycin, 1 μM
FCCP, 10 mM pyruvate, and 1 μM antimycin A. Each
plate had a subset of cells incubated with 10 mM nico-
tinamide adenine dinucleotide (NAD+, during the DM
pre-incubation) prior to measurements.
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Following calibration of the Seahorse XF24-3 flux analyzer
(Seahorse Bioscience), the final non-synaptic mito-
chondrial pellets from individual mouse brains were
resuspended in MAS1 buffer [25] and 5 μg protein as
determined above [24] loaded into each of 20 wells of
an XF24 V7 cell culture plate (Seahorse Bioscience).
The plates were centrifuged at 1,600 × g at 4°C
for 5 min. MAS1 buffer with 5 mM L-malate plus
5 mM sodium pyruvate (freshly made in MAS1 buffer)
was gently added to the wells and the plates immedi-
ately loaded onto the instrument and oxygen con-
sumption measurements were recorded as previously
described [14]. All measurements were performed at
37°C.Immunoblotting
Proteins as determined by [24] from brain homogenates
or non-synaptic mitochondria (50 μg) of APP(swe)/PS1
(ΔE9) and their non-transgenic litter mates (3 months)
were resolved using sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) on precast
Mini-Protean TGX any KD gels (Bio-Rad, Hercules,
CA) and transferred to a polyvinylidene difluoride
membrane using a Trans-Blot Turbo transfer system
(Bio-Rad). Immunoblotting was performed according
to Li-Cor Biosciences (Lincoln, NE) protocol. Briefly,
nonspecific sites were blocked in non-mammalian
blocking buffer (Li-Cor Biosciences). After blocking,
the membranes were incubated with primary anti-
bodies to Beta amyloid 1–16 (6E10, 1:1,000; Covance);
Histone deacetylase sirtuin 1 (SIRT1, 1:500; Millipore);
NAD+ glycohydrolase CD38 (CD38; 1:2,000; R&D,
Minneapolis, MN); Dynamin-related protein 1 (DRP1,
1:1,000; BD Biosciences, San Jose, CA); Phospho-DRP1
(P616-DRP1, 1:1,000; Cell Signaling Technology, Danvers,
MA); Mitofusin 2 (MFN2, 1:1,000; Abcam, Cambridge,
MA); Optic atrophy protein (OPA1, 1:1,000; BD Bio-
science); Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; 1:14,000; Cell Signaling Technology); Voltage
dependent anion channel (VDAC, 1:1,000; (rabbit); Cell
Signaling Technology); VDAC (mouse; 1:1,000; Mitos-
ciences (Eugene, OR); β-Actin (1:10,000; Sigma) at 4°C
overnight. After 4 × 5 min washes in phosphate buffered
saline (PBS) with 0.1% tween-20 (PBST), the membranes
were incubated in the appropriate infrared (IR) fluoro-
phore conjugated secondary antibody (Li-Cor Biosciences)
for 30 min in the dark. Following PBST washes, the IR sig-
nal was captured on an Odyssey infrared imaging system
(Li-Cor Biosciences) and stored as a digital image. VDAC
was utilized as the loading control for mitochondria and
GAPDH or β-Actin for brain homogenate to ensure equal
loading.Histology
Male and female CaMK2a-mito/eYFP, (3 months) were
perfusion-fixed under deep anesthesia then processed as
previously described [26].
Laser scanning confocal microscopy and quantitation of
mitochondrial morphology
Forty μm-thick coronal brain tissue sections from
CaMK2a-mito/eYFP mice (3 months) were washed
with potassium phosphate buffered saline (KPBS) then
mounted and coverslipped using Vectashield Hard set
(Vector, Burlingame, CA) mounting media. Mitochondria
in brain sections from CA1 hippocampal sub-regions were
imaged utilizing a Zeiss LSM 510 laser scanning confocal
microscope using a Plan-Apochromat 63x/1.4 oil lens.
Single planes of 1024 × 1024 pixels were recorded at 1.0 –
1.5 Airy unit pinhole every 0.2 μm z-spacing throughout
the entire tissue section as previously described [26] with
modifications. Specifically, z-stack images were obtained
from the striatum oriens of the CA1 sub-region. A
488 nm laser was used to visualize eYFP. Four z-stack im-
ages were taken per mouse brain. Recorded images were
analyzed with Volocity software (Perkin Elmer, Waltham,
MA). Quantification of mitochondrial morphology utiliz-
ing Volocity software was performed as previously de-
scribed [26]. The following equation was used to
determine 3D shape factor (ratio of the surface area of a
sphere (with the same volume as the given object) to the
surface area of the object): V0 = volume of object; A0 =
area of object
3D Shape Factor ¼ π
1=3 6V 0ð Þ2=3
A0
Statistical analysis
Data are expressed as means ± SE, and the comparisons
between experimental groups were made with SPSS stat-
istical software (SPSS, Inc., Chicago, IL) using analysis of
variance (ANOVA). Posthoc Holm-Sidak method was
used for all pairwise comparisons after ANOVA tests.
Student t-test was used when direct comparison of two
groups were analyzed (volocity data). Significance was
assumed at p < 0.05.
Results
Exogenous NAD+ reverses deficient oxygen consumption
rates (OCR) in a cell-based model of amyloid beta toxicity
N2A hippocampal neuroblastoma cells were transiently
co-transfected with constructs containing mutant APP
(swe)/PS1(ΔE9) and a tetracycline transactivator (TTA) as
a cell-based model of effects of mutant amyloid toxicity.
Co-transfected (transfected) or TTA-transfected (con-
trol) N2A cells were pre-incubated ± nicotinamide
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tion rates (OCR) measured. Transfected N2A cells (no
exogenous NAD+; blue dashed line) had decreased
maximal OCR when challenged with uncoupler car-
bonyl cyanide p-(trifluoromethoxy) phenylhydrazone
(FCCP) and pyruvate, compared to control cells +
NAD+ (24% decrease; Figure 1, red solid line); or con-
trol cells without exogenous NAD+ addition (18% de-
crease; Figure 1, red dashed line). This OCR deficit
(Figure 1, blue dashed line) could be ameliorated if ex-
ogenous NAD+ was present (27% increase; Figure 1,
blue solid line). Control N2A cultures had similar
OCR regardless of NAD+ addition (Figure 1, red solid
versus red dashed line). These experiments suggest
that deficiencies in NAD+ levels could play a role in
mitochondrial respiratory dysfunction in transgenic
mice expressing this mutation in vivo [14] and could
be corrected with added NAD+.Decreased full-length mutant human Amyloid Precursor
protein (APP) levels in brain of NMN treated transgenic mice
Forebrain homogenates were assessed for relative
transgene-derived full-length APP expression in both
APP(swe)/PS1(ΔE9) transgenic (AD-Tg) and non-transgenic
(NTG) mice (3 months). There were significantly (p <
0.05) increased mutant full-length APP levels in the brain
homogenates from the AD-Tg mice regardless of treat-
ment when compared to non-transgenic littermates. There
was a significant (p ≤ 0.05) decrease (38%) in full-length
mutant APP levels in brain homogenates of AD-Tg mice
treated with NMN as compared to AD-Tg vehicle-treated
mice (Figure 2).Figure 1 OCR in APP(swe)-overexpressing N2A hippocampal neuroblas
Baseline-normalized oxygen consumption rates (OCR) of N2A neuroblastom
modulators (arrows) are shown. Cells received 1 μg/ml oligomycin (Oligo),
Subsets of the cells (solid lines) were pre-incubated with 10 mM nicotinam
cells (dashed lines) had no exogenous NAD+. Rates are normalized to the t
2 separate cultures.Oxygen consumption deficits in brain mitochondria
isolated from AD-Tg mice are reversed by nicotinamide
mononucleotide (NMN)
In a previous study, we determined that brain mitochon-
drial ADP-stimulated OCR were significantly deficient in
3 months old male AD-Tg mice as compared to their
non-transgenic littermates [14]. NAD+ as a cofactor for
tricarboxylic acid (TCA) cycle and Complex I enzymatic
reactions and deficiencies give rise to bioenergetic dys-
function. The NAD+ precursor nicotinamide mononu-
cleotide (NMN) inhibits NAD+ degradation as well as
enhancing its synthesis [27]. Therefore, to examine the
potential relationship between mitochondrial respiratory
dysfunction and NAD+ catabolism, AD-Tg and non-
transgenic (NTG) mice (2 months) were given NMN or
phosphate buffered saline (PBS, vehicle). Non-synaptic
mitochondria were then isolated from the forebrains of
male and female (3 months) AD-Tg mice and their NTG
littermates. There were no significant differences in basal
OCR between the transgenic and non-transgenic mice
regardless of NMN treatment (Figure 3, Basal). However,
following addition of ADP to initiate State 3 respiration,
the AD-Tg vehicle-treated mice had significantly lower
OCR (p < 0.01) compared to the NTG animals (Figure 3,
ADP) recapitulating our previous study [14]. The AD-Tg
vehicle-treated mice were significantly deficient (p <
0.01) in State 3 respiration as compared to the trans-
genic mice that received NMN treatment (Figure 3,
ADP). Interestingly, the AD-Tg NMN-treated mice had
significantly increased (p < 0.01) OCR as compared to
the non-transgenic animals (Figure 3, ADP). Following
oligomycin addition reducing the rate of O2 consump-
tion to that of State 4° respiration, there was notoma cells (blue lines) and control transfected cells (red lines).
a cells exposed to successive additions of mitochondrial respiratory
1 μM FCCP, 10 mM pyruvate (Pyr), and 1 μM antimycin A (Ant A).
ide adenine dinucleotide (NAD+) prior to measurements while control
hird baseline measurement point for n = 3–5 replicates per group from
Figure 2 Full-length, transgene-derived amyloid precursor protein (APP) levels in brain homogenates following NMN treatment. (A)
Representative Western blots of homogenates isolated from the brains of AD-Tg and non-transgenic (NTG) mice (3 months) probed with 6E10
antibody. (B) Transgene-derived full-length APP (~106kD) is observed in AD-Tg mice with negligible levels in the NTG mice. Full-length APP levels
(ratio of APP:β-Actin) are significantly decreased in NMN-treated transgenic (AD-Tg NMN) mice compared to AD-Tg vehicle-treated. Data are
presented as the average full-length APP ± SE. N = 6 separate animals per group. *p < 0.05.
Figure 3 OCR deficits in non-synaptic brain mitochondria from mutant APP expressing mice following NMN treatment. Average OCR
(pMoles/min) in non-synaptic mitochondria isolated from APP(swe)/PS1(ΔE9) (AD-Tg) and non-transgenic (NTG) mouse (3 months) brain. Solid black
bar (NTG vehicle control), white bar (AD-Tg vehicle control) and striped bar (AD-Tg NMN). Data are presented as the average OCR ± SE. N = 3–5
separate animals per group. *p < 0.01.
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and non-transgenic mice regardless of treatment group
(Figure 3, Oligo). Although, following addition of FCCP
to assess maximal OCR there was no significant differ-
ence between NTG vehicle and AD-Tg vehicle-treated
mice, the AD-Tg NMN-treated mice had significantly
increased (p < 0.01) OCR as compared to both the
transgenic vehicle-treated and non-transgenic animals
(Figure 3, FCCP).
Histone deacetylase sirtuin1 (SIRT1) and CD38 protein
levels in brain homogenates
NAD+ is utilized as an important cofactor in many
metabolic reactions [28] including oxidative phosphoryl-
ation and enzymatic reactions of the TCA cycle [5], and
as a substrate for enzymes including histone deacetylase
sirtuin 1 (SIRT1), poly(ADP-ribose) polymerase 1 (PARP1)
and NAD+ glycohydrolase CD38. We assessed brain
homogenates from AD-Tg and non-transgenic NMN- and
vehicle-treated mice to determine if NAD+ catabolism wasFigure 4 Immunoreactivity of SIRT1 in homogenates isolated from NT
represents a different animal. (A) Representative Western blot images. (B) S
AD-Tg (vehicle) homogenates compared to NTG vehicle-treated animals. Th
AD-Tg mice although they remain significantly elevated. NTG SIRT1 levels n
as the average SIRT1 ± SE. N = 6 separate animals per group. **p≤ 0.05.due to increased SIRT1 levels. There was a significant in-
crease (p < 0.05) in SIRT1 immunoreactivity in brain ho-
mogenates from AD-Tg mice when compared to both
NTG animals as well as AD-Tg animals pre-treated with
NMN (Figure 4). Although the AD-Tg mice pre-treated
with NMN had lower SIRT1 immunoreactivity compared
to non-NMN treated AD-Tg mice, these levels were still
significantly elevated (p ≤ 0.05) as compared to NTG
animals (Figure 4).
SIRT1 immunoreactivity in brain homogenates was
examined to assess potential additive effects of AD
transgenes in older animals (3–9 months). There was
significantly (p < 0.05) increased SIRT1 immunoreac-
tivity in the 9 months AD-Tg mice as compared with
both the 3 and 6 months animals (Figure 5A, B). Fur-
ther, the 6 months AD-Tg SIRT1 levels were also
significantly (p ≤ 0.05) elevated compared to the
3 months AD-Tg mice (Figure 5A, B). As described
above, an alternative NAD+ consumer is the NAD+
glycohydrolase CD38 (CD38). We therefore also probedG and AD-Tg mouse brain following NMN treatment. Each lane
ignificantly increased SIRT1 levels (ratio SIRT1:GAPDH) are observed in
ese levels are significantly reduced (~49%) by the addition of NMN in
ormalized to GAPDH = 0.004 as presented in (B). Data are presented
Figure 5 Altered SIRT1 and CD38 immunoreactivity with age. Representative Western blot images for SIRT1 (A) and CD38 (C) in brain
homogenates isolated from NTG and AD-Tg mice (3–12 months). (B) Significantly increased SIRT1 levels (ratio SIRT1:GAPDH) are observed in
AD-Tg homogenates of 6 months compared to 3 months; and 9 months compared to both 3 and 6 months. (D) Significant increases in CD38 levels
are observed at 3 and 12 months in AD-Tg homogenates compared to NTG mice. Significant decrease in CD38 levels are observed at 6 months in
AD-Tg homogenates compared to 3 months AD-Tg mice. Data are presented as the average SIRT1 or CD38 ± SE. N = 3 separate animals per age group.
**p < 0.05; *p < 0.01; a: AD-Tg significantly different from NTG; b: 6 months AD-Tg significantly different from 3 months AD-Tg.
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3–12 months utilizing Western blots. There was a signifi-
cant increase (p < 0.05) in CD38 immunoreactivity in the
3 and 12 months AD-Tg mice as compared to age-
matched NTG animals (Figure 5C,D). There was a signifi-
cant decrease (p < 0.05) in CD38 immunoreactivity be-
tween 3 and 6 months AD-Tg mice (Figure 5C,D). There
was no significant difference in CD38 immunoreactivity in
NTG mice across the age groups examined. Although
there was an overall significant difference in CD38 levels
comparing genotypes (p < 0.01) or age (p < 0.01), there
was no genotype x age interaction (Figure 5C, D).
Morphological analyses of brain mitochondria from
CaMK2a-mito/eYFP mice
To begin examining potential explanations for the ameli-
orative benefits following in vivo addition of the NAD+
precursor NMN, we examined morphological parame-
ters in brain tissue of mice (3 months) possessing
mitochondrial-targeted fluorescent proteins in neurons
(CaMK2a-mito/eYFP mice). Mitochondrial morphology
has been demonstrated to influence respiration rates,
calcium homeostasis and organelle transport [15,16].
Brain mitochondrial respiratory rates in CaMK2a-
mito/eYFP mice have been previously determined to be
similar to the rates in wildtype mice [21] and therefore
can be utilized as an important tool to examine morph-
ology. Following the same protocol for NMN treatmentas described in the AD animals above, CaMK2a-mito/
eYFP mice given vehicle had more fragmented neuronal
mitochondria in the CA1 region of the hippocampus
when compared to CaMK2a-mito/eYFP animals given
NMN (Figure 6A). The CaMK2a-mito/eYFP mice
given NMN had far less fragmented mitochondria, but
had longer neuronal mitochondria in the CA1 region
(Figure 6B).
We next examined the shape of fluorescent neuronal
mitochondria in the CaMK2a-mito/eYFP mice. Shape
factor is a numerical value indicating how similar a 3D
shape is to a perfect sphere. Thus, a shape factor value
of 1 was considered to be completely spherical whereas
the closer to zero was considered to be rod-shaped.
Figure 6C diagrams the relative counts comprising the
shape factor value of neuronal mitochondria from
NMN-treated versus vehicle-treated mice. When the
shape of neuronal mitochondria in the CA1 hippocam-
pal region were examined, there was a significant (p <
0.05) increase in rod-shaped mitochondria in NMN-
treated mice compared to vehicle-treated animals
(Figure 6D). There was a reciprocal decrease in spherical-
shaped mitochondria in these same regions in NMN-
treated mice as compared to vehicle-treated animals that
were significantly (p < 0.05) altered (Figure 6D). Interest-
ingly, there was a significant (p < 0.05) difference between
rod and spherical-shaped mitochondria in the vehicle-
treated mice but no significant shape difference in the
Figure 6 Changes in mitochondrial dynamics following NMN treatment in CA1 hippocampal neurons from CAMK-eYFP mice.
Representative confocal images of control (A) and NMN-treated (B) neuronal mitochondria in the CA1 hippocampal sub-region. The fluorescent
mitochondria appear more fragmented (see white arrows) in the control image compared to NMN treatment that clearly demonstrates more
elongated mitochondria. Graphs (C, D) show the relative shape distribution and the relative mitochondrial length distribution (E, F) of different
mitochondrial populations. Scale bar in panels (A) and (B) represents 5 μm. **p < 0.05; *p < 0.01.
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tion of fluorescent neuronal mitochondria in the CA1 hip-
pocampal regions, there was a significant difference in
mitochondrial skeletal length when comparing NMN
treated and vehicle treated CaMK2a-mito/eYFP mice
(Figure 6E, F). The relative counts for skeletal length were
sub-divided into “spherical” (0–2 μm), “rod shaped” (2.2-
6 μm) and “tubular” (6.2-15 μm). The control mice had
significantly (p < 0.05) increased “spherical” length
mitochondria compared to the NMN treated animals
(Figure 6F). Conversely, the control mice had signifi-
cantly decreased “rod shaped” (p < 0.01) and “tubular”
(p ≤ 0.001) length mitochondria compared to NMN
treated animals (Figure 6F). There were no significant
differences in the relative counts for total volume or
total surface area between treatment groups (data not
shown). Further, the total number of mitochondria
approached significance with a trend toward lessmitochondria in NMN-treated mice (p = 0.066), as
compared to vehicle-treated animals (data not shown).
Together, these data suggest that NMN treatment
gives rise to longer mitochondria in the hippocampal
sub-region examined, likely through increased fusion
and/or decreased fission.
Altered Drp1 phosphorylation mediates mitochondrial
fragmentation in AD-Tg mice
Mitochondrial morphology is modulated by a dynamic
balance between fragmentation (fission) and formation
of tubular elongated structures (fusion) (reviewed in
[29,30]. Fission and fusion protein immunoreactivity was
therefore examined in mitochondria isolated from the
NTG and AD-Tg mice above that were given NMN or
vehicle.
The dynamin-related protein 1 (DRP1) with mito-
chondrial fission 1 protein (Fis1) control mitochondrial
Long et al. BMC Neurology  (2015) 15:19 Page 10 of 14fragmentation. When DRP1 immunoreactivity was assessed
in isolated brain mitochondria, there was a trend toward an
increase in DRP1 immunoreactivity in AD-Tg mice as com-
pared to NTG animals (p = 0.072) that was not changed in
the NMN-treated cohort (Figure 7A, B). When DRP1 is
phosphorylated at a specific serine residue (Ser616, P616-
DRP1), stabilization of the outer membrane of cytoplasmic
DRP1 occurs [31]. There was a significant (p < 0.05) in-
crease in P616-DRP1 immunoreactivity in mitochondria iso-
lated from AD-Tg mice as compared to NTG animals
(Figure 7A, C). The AD-Tg mice treated with NMN had
significantly (p < 0.05) decreased P616-DRP1 immunoreac-
tivity as compared to AD-Tg vehicle-treated animals
(Figure 7A, C). There was no significant difference in
mitochondrial P616-DRP1 immunoreactivity between
NTG animals and AD-Tg mice treated with NMN
(Figure 7A, C).Figure 7 Immunoreactivity of fission/fusion proteins in brain mitocho
Representative Western blot images of fission (DRP1 and phosphorylated fo
showing quantification of the Western blots in (A). The OPA1 oligomeric co
[32]. Voltage-dependent anion channel (VDAC) was utilized as a loading co
MFN2 ± SE. N = 5–7 separate animals per group. **p < 0.05.OPA1 and MFN2 immunoreactivity are differentially
altered in AD-Tg mice
We next examined immunoreactivity in these samples
for mitofusin 2 (MFN2) and optic atrophy protein
(OPA1), both associated with mediation of mitochon-
drial fusion.
Optic atrophy 1 (OPA1) is a dynamin-related GTPase
that resides in the mitochondrial inner membrane
(IMM) promoting regulation of mitochondrial fusion
[32]. OPA1 as an oligomeric complex in healthy mito-
chondria maintains cristae integrity. The oligomeric
complex comprises a heterotrimer formed by integral
IMM (long form ~100 kD; OPA1-L) and soluble inter-
membrane space (IMS, short form ~80 kD; OPA1-S)
forms of OPA1. There was a significant (p < 0.05) in-
crease in OPA1-L immunoreactivity in AD-Tg mice
compared to both NTG animals and AD-Tg mice thatndria isolated from mouse brain following NMN treatment. (A)
rm P616-DRP1) and fusion (OPA1 and MFN2) proteins. (B-F) Graphs
mplex comprises the long (L) fusogenic form and the short (S) form
ntrol. Data are presented as the average DRP, P616-DRP1, OPA1L OPA1S,
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cant difference in OPA1-L immunoreactivity between
the NTG and AD-Tg mice that received NMN (Figure 7A,
D). There was no significant difference in immunoreactiv-
ity across groups for the OPA1-S form (Figure 7A, E).
Mitofusin 2 (MFN2) also a GTPase is involved in fu-
sion of the mitochondrial outer membrane (OMM).
There were no significant differences in MFN2 levels
across groups (Figure 7A, F). Taken together, these data
demonstrate that the AD-Tg mice have increased mito-
chondrial fragmentation compared to NTG animals and
also mitochondrial fusion occurring which is ameliorated
in the transgenic mice given exogenous NMN.
Discussion
Alzheimer’s disease, along with other neurodegenerative
diseases, has a complex multifactorial pathology with
known mitochondrial deficits. This study is the first to
directly examine the amelioration of NAD+ catabolism
and changes in mitochondrial morphological dynamics
in AD mouse brain utilizing the immediate precursor
nicotinamide mononucleotide (NMN) as a potential
therapeutic compound. At three months, the well-
studied AD chimeric APP(swe)/PS1(ΔE9) (AD-Tg) mouse
model have mitochondrial oxygen consumption rate
(OCR) deficits [14] that precede amyloid deposition and
plaque formation in brain [33]. In the present study, de-
ficiencies in OCR were successfully reversed using the
same murine AD model administered NMN. In addition,
NMN reduced levels of full length mutant APP in the
AD-Tg mice. Further, the effects of NMN on normal
mitochondrial morphology were examined using mice
possessing fluorescent proteins targeted to neuronal
mitochondria (CaMK2a-mito/eYFP) and demonstrate
mitochondrial elongation and decreased fragmentation
in NMN treated animals.
Nicotinamide (NAM) administration has been demon-
strated to cross the blood–brain barrier and be con-
verted to NAD+, thus increasing cellular NAD+ levels in
the brain [34]. Further, NMN has been shown to be
highly enriched in mitochondria by sub-cellular fraction-
ation studies suggesting intramitochondrial NAD+ syn-
thesis [35] and may inhibit CD38 NAD+ glycohydrolase
activity [27,36]. Several disease/injury model studies have
previously utilized NMN as a therapeutic to ameliorate
NAD+ deficiencies.
Yoshino et al. [37] reversed NAD+ deficits in a diabetic
mouse model with intraperitoneal (IP) injections of
NMN (500 mg/kg body weight/day for 7 days) a higher
total dosage compared to the present study. In a separ-
ate study, NAD+ levels were increased within 30 minutes
after NMN administration (IP, 500 mg/kg body weight)
directly following ischemia and reperfusion in mouse
heart [9]. Further, NMN prevented decreases in NAD+ ifinjected 30 minutes prior to the insult [9]. In a cell cul-
ture model of Parkinson’s disease consisting of rotenone
treated PC12 cells, NMN intervention reduced apoptosis
and restored intracellular levels of NAD+ and ATP [11].
In the present study, we used early low dose NMN ad-
ministration beginning at two months of age to prevent
the OCR deficits seen previously in three months old
AD-Tg mice [14].
Studies of NAD+ deficiencies in diabetes, hepatic stea-
tosis, and aging have historically used the NAD+ salvage
pathway supplements: NAM or nicotinic acid (NA)
[38,39]. Nicotinic acid can bind to the GPR109A re-
ceptor, a G protein-coupled receptor that binds NA
resulting in severe flushing as a side effect, making it
unfavorable to most patients [39]. Alternatively, nico-
tinamide riboside (NR) and NMN do not bind to the
GPR109A receptor and are considered to have fewer
unfavorable side effects [39]. Several studies have
looked at NAM and NR as possible therapeutics for
Alzheimer's disease, although none have used NMN.
Liu et al. [40] administered NAM for 8 months in
triple transgenic AD mice, finding NAM reduced beta
amyloid (Aβ) and tau pathologies, elevated brain NAD
+ levels, improved brain bioenergetics, and preserved
mitochondrial functionality. In a separate study, Green
et al. [41] treated four months old triple transgenic
AD mice for 4 months, finding NAM treatment de-
creased tau levels and improved cognition. Similarly,
when adult neurons isolated from triple transgenic AD
mice aged 2 or 21 months were treated with NAM for
15 hours, NADH regenerating capacity was completely
restored [42]. In a different AD disease mouse model,
Gong et al. [43] treated Tg2576 animals with NR from
5–6 month of age until 10–11 months of age. NR
treated mice had increased brain NAD+ levels, elevated
Peroxisome proliferator-activated receptor gamma coacti-
vator 1-alpha (PGC-1α), reduced Aβ, and reduced Beta
site APP cleaving enzyme 1 (BACE1) [43]. Our present
study is the first report using NMN in any AD mouse
model, treating them temporally prior to amyloid depos-
ition to focus on mitochondrial bioenergetics.
Sirtuins (SIRT 1–7) are class III histone deacetylases
and NAD+ dependent enzymes [44]. Activation of
SIRT1 mainly exerts neuroprotective actions [1] for
example by deacetylating target proteins including
PGC-1α, demonstrated to be deficient in human AD
brain [45]. PGC-1α activation gives rise to mitochondrial
biogenesis. In another study in APP/PS1 AD mice, overex-
pression of SIRT1 improved behavior and reduced Aβ
[46]. In the present study, AD-Tg mice had significantly
increased SIRT1 immunoreactivity compared to non-
transgenic (NTG) mice that NMN treatment reduced
(Figure 4) potentially preserving overall NAD+ pools for
functional mitochondrial energetics.
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could also be influenced by dynamic efficiency and the
balance between fission and fusion. Mitochondrial fusion
is regulated by the short and long isoforms of the pro-
tein Optic atrophy 1 (Opa1), as well as Mitofusin pro-
teins (Mfn1 and Mfn2). Long and short OPA1 isoforms
are both required for fusion. There is a reduction in fu-
sion and an increase in fragmentation when the long
OPA1 isoforms are converted to the short soluble OPA1
isoforms [47]. This can be the result of a reduction in
mitochondrial membrane potential and can lead to
mitophagy and cellular death [47]. Mitochondrial fission
is regulated by Dynamin related protein Drp1, specific-
ally by post-translational modifications of Drp1 [18].
Short round mitochondria occur more commonly with
dysfunctional mitochondria resulting from treatment
with a toxin or mtDNA depletion [48]. In this study we
found a significant increase in P616-DRP1 immunoreac-
tivity in AD-Tg mouse mitochondria compared to NTG
and AD-Tg NMN treated animals. This would indicate
AD-Tg mice might have more fission and fragmentation
of mitochondria than the NTG mice. Furthermore,
NMN reduced fission in the treated AD-Tg mice revert-
ing P616-DRP1 levels to those of NTG animals.
To more clearly investigate mitochondrial morph-
ology, CA1 hippocampal sections from CaMK2a-mito/
eYFP mice were examined. These bigenic mice were pre-
viously determined to have functional mitochondrial
bioenergetics similar to non-transgenic littermates
[21]. NMN treated CaMK2a-mito/eYFP mice had lon-
ger mitochondria and reduced fragmentation, while
vehicle treated mice had a greater proportion of spher-
ical shaped mitochondria, possibly indicating more fis-
sion. There were no differences in total mitochondrial
volume and the NMN treated samples had slightly
fewer mitochondria, suggesting, NMN reduces fission
or increases fusion. Taken together, NMN treatment
decreased fission (P616-DRP1, AD mice) and reduced
fragmentation (CaMK2a-mito/eYFP mice) suggesting a
shift in dynamics from fission to fusion. This shift in
dynamics could explain amelioration of mitochondrial
bioenergetic deficits in the AD-Tg mice given NMN.
Conclusions
We have established a potentially promising therapeutic
protocol for the use of NMN as a viable supplement to
reduce the cellular NAD+ deficits found in an AD mouse
model. Administration of NMN improved mitochondrial
bioenergetics in an AD-Tg AD mouse model as well as
reduced mitochondrial fragmentation in mice possessing
fluorescent proteins targeted to neuronal mitochondria
without any observable negative side effects. The present
study used young AD-Tg mice that had yet to form Aβ
plaques given a low dose of NMN administered everyother day for one month. It remains unclear if NMN
prevented the mitochondrial deficits or remediated
them. Reduction of full-length mutant APP following
NMN treatment may also play a role in amelioration of
mitochondrial bioenergetic function. Further studies
need to be performed to examine potential benefit of
NMN administered to older mice with progressive dis-
ease pathology. Furthermore, it is unknown whether a
higher dose of NMN or longer duration of administration
would be even more beneficial. By showing NMN can im-
prove mitochondrial bioenergetics and dynamics in the
mouse brain, we conclude that NMN has the potential to
be a promising therapeutic for further testing on other
neurological disease models with known NAD+ deficits.
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